Christopher Simon - 29 Aug 2024 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Reporting relationship: President & CEO, Director
Issuer ticker: HAE
Reported as of: 29 Aug 2024
Net transaction value: -$3,000,034
SEC form: 4
Accepted by SEC: 03 Sep 2024, 16:20:34 UTC
Prior SEC filing: 09 Aug 2024
Next SEC filing: 19 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas V. Powers, attorney-in-fact for Mr. Simon

Key filing fact

Christopher Simon filed Form 4 for HAEMONETICS CORP (HAE) on 03 Sep 2024.

Key facts

This page summarizes Christopher Simon's Form 4 filing for HAEMONETICS CORP (HAE).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2024, 16:20.

Change

Previous filing in this sequence was filed on 09 Aug 2024.
Current net transaction value: -$3,000,034.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HAE transaction

Common Stock

Other

Transaction value: $3,000,034
Shares: -39,704
Change %: -11%
Price: $75.56
Shares after: 322,838
Date: 29 Aug 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On August 29, 2024, in an asset substitution transaction, Mr. Simon transferred 39,704 shares of the Issuer's common stock to the Simon Family Irrevocable Trust for the benefit of the reporting person's children, in exchange for cash in the amount of $3,000,034, with the number of shares determined by averaging the high and low sales prices of the Issuer's common stock as reported by the New York Stock Exchange on August 29, 2024. The substitution was made in accordance with the terms of the trust, which has an independent trustee.

Footnote F2

This number includes unvested restricted stock units previously reported.